Advances in small molecule maintenance therapies for high-grade serous ovarian cancer.
Margherita FischettiViolante Di DonatoInnocenza PalaiaGiorgia PerniolaFederica TomaoChiara PerroneAntonella GiancottiDaniele Di MascioMarco MontiLudovico MuziiPierluigi Benedetti PaniciGiorgio BoganiPublished in: Expert opinion on pharmacotherapy (2022)
Protein-targeted therapies against tumor tissues have progressed significantly in the last years due to an enhanced knowledge of the biological and molecular processes of carcinogenesis. Treatment with small molecules allows the targeting of specific proteins involved in cancer biology. TKIs seem promising but further data are necessary to assess the pros and cons of adopting this treatment modality. PARP inhibitors represent the new standard of care for ovarian cancer patients harboring either a BRCA mutation or with homologous recombination deficiency (HRD). Interestingly, the accumulation of data has highlighted that PARP inhibitors provide benefits even in patients with HR proficient tumors.